Financial Performance & Strategic Review - Charles River's Board supports the company's strategic direction, focusing on strengthening its scientific portfolio, divesting underperforming assets, maximizing financial performance, and maintaining disciplined capital deployment[7] - The company is refining its portfolio by selling certain underperforming or non-core businesses, representing approximately 7% of the estimated 2025 revenue[9] - These divestitures are expected to result in non-GAAP earnings per share accretion of at least $0.30 on an annualized basis once completed, excluding reinvestment benefits or interest expense impacts[9] - A new $1.0 billion stock repurchase authorization was approved by the Board in October, replacing a previous authorization under which $450.7 million in common stock had been repurchased since August 2024[10] 3Q25 Results & Updated Guidance - 3Q25 revenue was $1,004.9 million, a 0.5% decrease compared to $1,009.8 million in 3Q24, with a 1.6% organic revenue decline[13] - The GAAP EPS for 3Q25 was $1.10, a 17.3% decrease from $1.33 in 3Q24, while the non-GAAP EPS was $2.43, a 6.2% decrease from $2.59[15] - The company revised its 2025 revenue growth guidance to a decline of 1.5%-0.5% reported and a decline of 2.5%-1.5% organic[16] - The 2025 non-GAAP EPS estimate is now $10.10-$10.30, which includes a $0.10 guidance improvement at the midpoint[36] Segment Performance & Outlook - DSA (Discovery and Safety Assessment) revenue for 3Q25 was $600.7 million, a 2.3% decrease compared to $615.1 million in 3Q24, with a 3.1% organic revenue decline[17] - RMS (Research Models and Services) revenue for 3Q25 was $213.5 million, a 7.9% increase compared to $197.8 million in 3Q24, with a 6.5% organic revenue growth[25] - Manufacturing revenue for 3Q25 was $190.7 million, a 3.1% decrease compared to $196.9 million in 3Q24, with a 5.1% organic revenue decline[28]

Drug Discovery Timeline - Isomorphic Labs的目标是将药物发现的时间从几年缩短到几个月，甚至更快[1][2] - Demis Hassabis认为，随着Isomorphic Labs的平台在未来几年内成熟，这一目标是可能实现的[1] AI's Role in Drug Discovery - AI技术的进步可能将药物发现的时间大大缩短[2] - Isomorphic Labs正在利用统一的药物设计引擎，加速药物开发，并寻找解决世界最具挑战性疾病的方法[1] Isomorphic Labs' Mission - Isomorphic Labs的使命是利用AI技术攻克癌症[2] - Isomorphic Labs致力于更快地将药物送到患者手中[1]

Company Activities - Isomorphic Labs' President Colin Murdoch will speak at VivaTech 2025 in Paris about AI's potential for drug discovery [1] - Colin Murdoch will participate in an AI Drug Discovery panel discussion on June 12 (2:50 - 3:15 PM CEST) [1] - Colin Murdoch will have a fireside chat on June 13 (10:30 - 10:55 AM CEST) [1] Industry Collaboration - The AI Drug Discovery panel includes NVIDIA's Vice President, Healthcare and Life Sciences [1] - The fireside chat will be with Melissa Hei from the FT (Financial Times) [1]